Terms: = Uterine cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Treatment
4 results:
1. The mutational repertoire of uterine sarcomas and carcinosarcomas in a Brazilian cohort: A preliminary study.
da Costa LT; Dos Anjos LG; Kagohara LT; Torrezan GT; De Paula CAA; Baracat EC; Carraro DM; Carvalho KC
Clinics (Sao Paulo); 2021; 76():e2324. PubMed ID: 33503190
[TBL] [Abstract] [Full Text] [Related]
2. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors.
Zibetti Dal Molin G; Westin SN; Msaouel P; Gomes LM; Dickens A; Coleman RL
Int J Gynecol Cancer; 2020 Jan; 30(1):89-93. PubMed ID: 31792084
[TBL] [Abstract] [Full Text] [Related]
3. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract] [Full Text] [Related]
4. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells.
Bacus SS; Yarden Y; Oren M; Chin DM; Lyass L; Zelnick CR; Kazarov A; Toyofuku W; Gray-Bablin J; Beerli RR; Hynes NE; Nikiforov M; Haffner R; Gudkov A; Keyomarsi K
Oncogene; 1996 Jun; 12(12):2535-47. PubMed ID: 8700512
[TBL] [Abstract] [Full Text] [Related]
